vs
Side-by-side financial comparison of Powerfleet, Inc. (AIOT) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
Powerfleet, Inc. is the larger business by last-quarter revenue ($113.5M vs $86.8M, roughly 1.3× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 6.6%). Powerfleet, Inc. produced more free cash flow last quarter ($4.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 81.2%).
Powerfleet, Inc. is an American company headquartered in Woodcliff Lake, New Jersey, that operates as a global provider of IoT and M2M solutions for securing, controlling, and tracking high-value enterprise assets. The company is a provider in the international telematics industry, providing fleet management, asset tracking, freight visibility, and driver behavior monitoring for industrial trucks, vehicle fleets, and shipping containers.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
AIOT vs IOVA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $113.5M | $86.8M |
| Net Profit | $-3.4M | — |
| Gross Margin | 55.2% | 67.4% |
| Operating Margin | 5.6% | -84.7% |
| Net Margin | -3.0% | — |
| Revenue YoY | 6.6% | 17.7% |
| Net Profit YoY | 76.6% | — |
| EPS (diluted) | $-0.03 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $113.5M | $86.8M | ||
| Q3 25 | $111.7M | $67.5M | ||
| Q2 25 | $104.1M | $60.0M | ||
| Q1 25 | $103.6M | $49.3M | ||
| Q4 24 | $106.4M | $73.7M | ||
| Q3 24 | $77.0M | $58.6M | ||
| Q2 24 | $75.4M | $31.1M | ||
| Q1 24 | — | $715.0K |
| Q4 25 | $-3.4M | — | ||
| Q3 25 | $-4.3M | $-91.3M | ||
| Q2 25 | $-10.2M | $-111.7M | ||
| Q1 25 | $-12.4M | $-116.2M | ||
| Q4 24 | $-14.3M | — | ||
| Q3 24 | $-1.9M | $-83.5M | ||
| Q2 24 | $-22.3M | $-97.1M | ||
| Q1 24 | — | $-113.0M |
| Q4 25 | 55.2% | 67.4% | ||
| Q3 25 | 56.0% | 43.0% | ||
| Q2 25 | 54.2% | 5.5% | ||
| Q1 25 | 52.8% | -0.8% | ||
| Q4 24 | 55.2% | 68.7% | ||
| Q3 24 | 53.7% | 46.2% | ||
| Q2 24 | 52.6% | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 5.6% | -84.7% | ||
| Q3 25 | 3.8% | -140.7% | ||
| Q2 25 | -2.0% | -189.8% | ||
| Q1 25 | -6.7% | -245.8% | ||
| Q4 24 | -1.2% | -117.5% | ||
| Q3 24 | 0.7% | -152.1% | ||
| Q2 24 | -24.2% | -327.6% | ||
| Q1 24 | — | -16464.6% |
| Q4 25 | -3.0% | — | ||
| Q3 25 | -3.8% | -135.3% | ||
| Q2 25 | -9.8% | -186.2% | ||
| Q1 25 | -12.0% | -235.5% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -2.5% | -142.7% | ||
| Q2 24 | -29.6% | -312.2% | ||
| Q1 24 | — | -15800.8% |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.08 | $-0.33 | ||
| Q1 25 | $-0.09 | $-0.36 | ||
| Q4 24 | $-0.11 | $-0.24 | ||
| Q3 24 | $-0.02 | $-0.28 | ||
| Q2 24 | $-0.21 | $-0.34 | ||
| Q1 24 | — | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.2M | $297.0M |
| Total DebtLower is stronger | $237.8M | — |
| Stockholders' EquityBook value | $485.0M | $698.6M |
| Total Assets | $959.5M | $913.2M |
| Debt / EquityLower = less leverage | 0.49× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.2M | $297.0M | ||
| Q3 25 | $27.9M | $300.8M | ||
| Q2 25 | $31.2M | $301.2M | ||
| Q1 25 | $44.4M | $359.7M | ||
| Q4 24 | $33.6M | $323.8M | ||
| Q3 24 | $26.0M | $397.5M | ||
| Q2 24 | $30.2M | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $237.8M | — | ||
| Q3 25 | $238.2M | — | ||
| Q2 25 | $239.0M | — | ||
| Q1 25 | $237.5M | — | ||
| Q4 24 | $238.5M | — | ||
| Q3 24 | $113.6M | — | ||
| Q2 24 | $113.7M | — | ||
| Q1 24 | — | — |
| Q4 25 | $485.0M | $698.6M | ||
| Q3 25 | $468.8M | $702.3M | ||
| Q2 25 | $460.7M | $698.5M | ||
| Q1 25 | $446.6M | $767.9M | ||
| Q4 24 | $458.4M | $710.4M | ||
| Q3 24 | $451.0M | $773.5M | ||
| Q2 24 | $390.4M | $768.5M | ||
| Q1 24 | — | $680.0M |
| Q4 25 | $959.5M | $913.2M | ||
| Q3 25 | $936.9M | $904.9M | ||
| Q2 25 | $930.8M | $907.4M | ||
| Q1 25 | $910.1M | $966.7M | ||
| Q4 24 | $908.7M | $910.4M | ||
| Q3 24 | $748.3M | $991.1M | ||
| Q2 24 | $684.9M | $964.3M | ||
| Q1 24 | — | $869.8M |
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.2M | $-52.6M |
| Free Cash FlowOCF − Capex | $4.9M | $-61.9M |
| FCF MarginFCF / Revenue | 4.4% | -71.3% |
| Capex IntensityCapex / Revenue | 4.6% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.2M | $-52.6M | ||
| Q3 25 | $5.5M | $-78.7M | ||
| Q2 25 | $4.7M | $-67.4M | ||
| Q1 25 | $13.5M | $-103.7M | ||
| Q4 24 | $-6.1M | $-73.3M | ||
| Q3 24 | $-3.2M | $-59.0M | ||
| Q2 24 | $-7.6M | $-98.4M | ||
| Q1 24 | — | $-122.3M |
| Q4 25 | $4.9M | $-61.9M | ||
| Q3 25 | $1.2M | $-89.5M | ||
| Q2 25 | $-3.4M | $-74.9M | ||
| Q1 25 | $10.1M | $-109.9M | ||
| Q4 24 | $-12.2M | $-77.5M | ||
| Q3 24 | $-8.0M | $-61.3M | ||
| Q2 24 | $-13.2M | $-98.9M | ||
| Q1 24 | — | $-126.5M |
| Q4 25 | 4.4% | -71.3% | ||
| Q3 25 | 1.1% | -132.7% | ||
| Q2 25 | -3.3% | -124.9% | ||
| Q1 25 | 9.8% | -222.8% | ||
| Q4 24 | -11.5% | -105.1% | ||
| Q3 24 | -10.4% | -104.6% | ||
| Q2 24 | -17.5% | -317.9% | ||
| Q1 24 | — | -17685.3% |
| Q4 25 | 4.6% | 10.7% | ||
| Q3 25 | 3.9% | 16.1% | ||
| Q2 25 | 7.8% | 12.4% | ||
| Q1 25 | 3.3% | 12.6% | ||
| Q4 24 | 5.8% | 5.7% | ||
| Q3 24 | 6.3% | 3.9% | ||
| Q2 24 | 7.4% | 1.4% | ||
| Q1 24 | — | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIOT
| Services | $91.1M | 80% |
| Products | $22.4M | 20% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
